HomeME • NASDAQ
add
23andMe Holding Co.
$3.16
Makalipas ang Oras ng Trabaho:(0.32%)-0.0100
$3.15
Sarado: Nob 26, 6:24:18 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$3.29
Sakop ng araw
$3.12 - $3.29
Sakop ng taon
$2.66 - $20.40
Market cap
71.98M USD
Average na Volume
429.70K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 44.07M | -11.86% |
Gastos sa pagpapatakbo | 81.33M | -17.18% |
Net na kita | -59.10M | 21.48% |
Net profit margin | -134.11 | 10.91% |
Kita sa bawat share | — | — |
EBITDA | -54.96M | 21.06% |
Aktuwal na % ng binabayarang buwis | 0.07% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 126.60M | -50.62% |
Kabuuang asset | 318.94M | -60.19% |
Kabuuang sagutin | 217.01M | 23.31% |
Kabuuang equity | 101.93M | — |
Natitirang share | 26.12M | — |
Presyo para makapag-book | 0.83 | — |
Return on assets | -42.89% | — |
Return on capital | -75.30% | — |
Cash Flow
Net change in cash
(USD) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | -59.10M | 21.48% |
Cash mula sa mga operasyon | -40.93M | 28.34% |
Cash mula sa pag-invest | -2.70M | 2.63% |
Cash mula sa financing | 260.00K | -83.68% |
Net change in cash | -43.37M | 25.18% |
Malayang cash flow | -12.82M | 59.90% |
Tungkol
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Itinatag
Abr 2006
Headquarters
Website
Mga Empleyado
571